Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Junliang Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0004-7213-5403; OpenAlex author ID A5076543204. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. Co-author DOI 10.1002/advs.202520029↗
  2. AI-driven tumor heterogeneity quantification and survival prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41746-026-02979-7↗
  3. Labor-Efficient Pathological Auxiliary Diagnostic Model for Primary and Metastatic Tumor Tissue Detection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2025.100764↗
  4. Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. Co-author DOI 10.1002/cam4.3679↗
  5. Interleukin-17 activates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.003↗
  6. AREG mediates the epithelial‑mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF‑κB signalling pathway. Co-author DOI 10.3892/or.2020.7523↗
  7. High-molecular-weight hyaluronan produced by activated pancreatic stellate cells promotes pancreatic cancer cell migration via paracrine signaling. Co-author DOI 10.1016/j.bbrc.2019.05.167↗
  8. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. Co-author DOI 10.1016/j.canlet.2019.07.015↗
  9. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Co-author DOI 10.1186/s13000-017-0678-4↗
  10. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrin… Co-author DOI 10.1016/j.canlet.2017.04.001↗
  11. Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13000-017-0633-4↗
  12. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13000-016-0512-4↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiyong Liang · 10 shared papers, 2016–2026 · strength 1.28
  2. Huanwen Wu · 10 shared papers, 2016–2026 · strength 1.17
  3. Xiaoding Liu · 2 shared papers, 2025–2026 · strength 0.42
  4. Zhiwen Zhang · 3 shared papers, 2018–2021 · strength 0.33
  5. Tonghua Liu · 4 shared papers, 2017–2019 · strength 0.32
  6. Haitao Zhang · 1 shared paper, 2026 · strength 0.22
  7. Zi Wang · 1 shared paper, 2026 · strength 0.22
  8. Lizhi Shao · 1 shared paper, 2026 · strength 0.22
  9. Lili Wang · 3 shared papers, 2016–2018 · strength 0.22
  10. Li Wang · 3 shared papers, 2016–2017 · strength 0.22
  11. Hangqi Liu · 1 shared paper, 2026 · strength 0.22
  12. Qixian Liu · 1 shared paper, 2026 · strength 0.22
  13. Xuqing Shi · 1 shared paper, 2026 · strength 0.22
  14. Menghua Dai · 1 shared paper, 2026 · strength 0.22
  15. Boju Pan · 1 shared paper, 2025 · strength 0.21
  16. Xiao Ke · 1 shared paper, 2025 · strength 0.21
  17. Lili Wang · 2 shared papers, 2017–2020 · strength 0.20
  18. Xiaolong Liang · 2 shared papers, 2018–2021 · strength 0.20
  19. Jian Hua Sun · 2 shared papers, 2018–2021 · strength 0.20
  20. Hui Zhang · 2 shared papers, 2017–2021 · strength 0.20
  21. Li Wang · 1 shared paper, 2020 · strength 0.13
  22. Rui Liu · 1 shared paper, 2021 · strength 0.12
  23. Liang Zhiyong · 1 shared paper, 2019 · strength 0.11
  24. Hongmei Dai · 1 shared paper, 2021 · strength 0.11
  25. Xianze Wang · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.